SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-018243
Filing Date
2023-03-07
Accepted
2023-03-07 16:17:46
Documents
13
Period of Report
2023-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174819-8k_tffpharma.htm   iXBRL 8-K 32019
2 PRESS RELEASE DATED MARCH 7, 2023 REGARDING THE REGISTRANT'S FINANCIAL RESULTS F ea174819ex99-1_tffpharma.htm EX-99.1 25007
  Complete submission text file 0001213900-23-018243.txt   240190

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE tffp-20230307_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tffp-20230307_pre.xml EX-101.PRE 22361
5 XBRL SCHEMA FILE tffp-20230307.xsd EX-101.SCH 3230
7 EXTRACTED XBRL INSTANCE DOCUMENT ea174819-8k_tffpharma_htm.xml XML 3710
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 23712832
SIC: 2834 Pharmaceutical Preparations